8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
Apr 27, 2026·SEC
Adagio Medical Holdings, Inc.(ADGM)Earnings, Financials & Key Ratios
ADGM•NASDAQ
$0.65
Price updated Jun 27, 2026
AboutAdagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.Show more
- Revenue$0-100.0%
- EBITDA-$21M+70.2%
- Net Income-$25M+53.3%
- EPS (Diluted)-1.51+57.3%
- ROE-155.25%+42.5%
ADGM Price & Volume
Adagio Medical Holdings, Inc. (ADGM) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Absence Strains Capital Runway Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Capital Runway and Dilution
"Adagio Medical Holdings remains a high-risk, pre-commercial entity struggling to establish a repeatable sales cycle for its cryoablation technology in a market increasingly dominated by Pulsed Field Ablation incumbents. The company faces significant structural headwinds, characterized by consistent quarterly operating losses of $5.2 million as of 2026Q1 and a rapidly thinning cash position. Investors should monitor the firm's ability to manage its rising debt-to-equity ratio of 4.21, which suggests a precarious reliance on external financing to sustain ongoing R&D operations."
Verdict Logic
the company's lack of revenue generation combined with a dwindling cash balance of $12.9 million as of 2026Q1 presents a substantial risk of further shareholder dilution.
ADGM Growth Metrics
Adagio Medical Holdings, Inc. (ADGM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM65.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM66.84%
Return on Capital
10 Years-9477.1%
5 Years-9477.1%
3 Years-18735.5%
Last Year-57.83%
ADGM Recent Earnings
Adagio Medical Holdings, Inc. (ADGM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/5 qtrs (33%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.31-6.9%
$0.29
Rev
—
—
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$0.21+32.3%
$0.31
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.66-53.5%
$0.43
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.35
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.31vs $0.29-6.9% | — |
| Q2 2026 | Mar 27, 2026 | $0.21vs $0.31+32.3% | — |
| Q4 2025 | Nov 12, 2025 | $0.66vs $0.43-53.5% | — |
| Q3 2025 | Aug 13, 2025 | $0.35 | — |
Based on last 5 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Adagio Medical Holdings, Inc. (ADGM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.65 | $9.83M | -0.43 | -100% | — | -155.25% | — | |
| $0.68 | $23.26M | -1.09 | — | — | -1034.04% | — | |
| $7.85 | $615.85M | 3.85 | 617.03% | 45.25% | 50.38% | — | |
| $30.18 | $1.53B | -125.75 | 14.88% | -0.83% | -0.95% | — | |
| $1.10 | $54.42M | -6.11 | -13.47% | 2.07% | 27.9% | — | |
| $527.07 | $15.05B | 34.49 | 19.97% | 17.19% | 120.89% | — |
Compare ADGM vs Peers
Adagio Medical Holdings, Inc. (ADGM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ADGM SEC Filings & Documents
Adagio Medical Holdings, Inc. (ADGM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ADGM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADGM Frequently Asked Questions
Adagio Medical Holdings, Inc. (ADGM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Adagio Medical Holdings, Inc. growing?
Adagio Medical Holdings, Inc. (ADGM) saw revenue decline by 100.0% over the past year.
Is ADGM profitable?
Adagio Medical Holdings, Inc. (ADGM) reported a net loss of $24.4M for fiscal year 2025.
Dividend & Returns
What is ADGM's return on equity?
Adagio Medical Holdings, Inc. (ADGM) has a return on equity (ROE) of -155.3%. Negative ROE indicates the company is unprofitable.
What is Adagio Medical Holdings, Inc.'s free cash flow?
Adagio Medical Holdings, Inc. (ADGM) had negative free cash flow of $15.6M in fiscal year 2025, likely due to heavy capital investments.